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Abstract
The limited efficacy of glucocorticoids (GCs) during therapy of acute relapses in multiple sclerosis (MS) leads to long-term 
disability. We investigated the potential of vitamin D (VD) to enhance GC efficacy and the mechanisms underlying this VD/
GC interaction. In vitro, GC receptor (GR) expression levels were quantified by ELISA and induction of T cell apoptosis 
served as a functional readout to assess synergistic 1,25(OH)2D3 (1,25D)/GC effects. Experimental autoimmune encepha-
lomyelitis  (MOG35–55 EAE) was induced in mice with T cell-specific GR or mTORc1 deficiency. 25(OH)D (25D) levels 
were determined in two independent cohorts of MS patients with stable disease or relapses either responsive or resistant to 
GC treatment (initial cohort: n = 110; validation cohort: n = 85). Gene expression of human  CD8+ T cells was analyzed by 
microarray (n = 112) and correlated with 25D serum levels. In vitro, 1,25D upregulated GR protein levels, leading to increased 
GC-induced T cell apoptosis. 1,25D/GC combination therapy ameliorated clinical EAE course more efficiently than respec-
tive monotherapies, which was dependent on GR expression in T cells. In MS patients from two independent cohorts, 25D 
deficiency was associated with GC-resistant relapses. Mechanistic studies revealed that synergistic 1,25D/GC effects on 
apoptosis induction were mediated by the mTOR but not JNK pathway. In line, 1,25D inhibited mTORc1 activity in murine 
T cells, and low 25D levels in humans were associated with a reduced expression of mTORc1 inhibiting tuberous sclerosis 
complex 1 in  CD8+ T cells. GR upregulation by 1,25D and 1,25D/GC synergism in vitro and therapeutic efficacy in vivo were 
abolished in animals with a T cell-specific mTORc1 deficiency. Specific inhibition of mTORc1 by everolimus increased the 
efficacy of GC in EAE. 1,25D augments GC-mediated effects in vitro and in vivo in a T cell-specific, GR-dependent manner 
via mTORc1 inhibition. These data may have implications for improvement of anti-inflammatory GC therapy.
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Introduction
Multiple sclerosis (MS) is an autoimmune disorder of the 
central nervous system. At disease onset, more than 80% 
of MS patients suffer from a relapsing disease course [15]. 
MS relapses are characterized by acute occurrence of new 
neurological symptoms or worsening of pre-existing defi-
cits due to acute focal autoimmune inflammation. Relapses 
often lead to sustained residual disability with almost 50% 
of patients suffering increased disability post-relapse [26]. 
High-dose intravenous glucocorticoid (GC) pulse therapy, 
i.e. 500–2000 mg methylprednisolone (MP) over 3–5 days, 
is the current standard treatment of acute MS relapses. A 
plethora of experimental data indicates that termination 
of the autoimmune inflammatory reaction by GCs attenu-
ates tissue damage [27]. Several mechanisms are consid-
ered to contribute to these profound anti-inflammatory 
effects, e.g. inhibition of pro-inflammatory mediators, 
inhibition of activation and migration of immune cells, 
and restoring integrity of the blood–brain barrier [27, 
46]. Induction of T cell apoptosis in both MS patients and 
experimental autoimmune encephalomyelitis (EAE), an 
animal model that mimics many features of MS, is also 
considered to contribute to the therapeutic mechanism of 
GCs [23, 44]. In EAE, GC efficacy is dependent on the 
presence of the glucocorticoid receptor (GR) expressed 
in T cells [52, 54]. Although GCs constitute the main-
stay of relapse therapy in MS, a considerable proportion 
of patients do not respond sufficiently [6]. This impaired 
clinical efficacy has been linked to altered levels of the 
GR and associated proteins [2]. Namely, reduced expres-
sion of the GR in peripheral blood mononuclear cells of 
GC-resistant MS patients was accompanied by increased 
levels of the chaperone heat shock protein (hsp) 90 [29]. In 
addition, a downregulation of the GR was detected in GC-
resistant T cells obtained during myelin oligodendrocyte 
 glycoprotein35–55  (MOG35–55) EAE [14]. Clinically, over-
coming GC resistance remains an unmet need in MS ther-
apy. Several lines of evidence indicate that vitamin D (VD) 
could augment GC-induced immune effects. For instance, 
VD pre-treatment increased dexamethasone-induced bind-
ing of the GR to GC response elements in monocytes from 
patients with GC-resistant asthma [57]. Furthermore, VD 
restored the efficacy of GCs to induce IL-10 production in 
T-helper cells [55]. Hypothetically, the inhibition of mam-
malian target of rapamycin (mTOR) by VD could medi-
ate such a synergistic effect, since in malignant lymphoid 
cells in vitro resistance to GCs appears to be reversible 
after application of the mTOR inhibitor rapamycin [31]. 
The mTOR pathway controls cell differentiation and sur-
vival by integrating multiple environmental cues such as 
stress, oxygen supply, growth factors and amino acids. In 
particular, mTORc1 regulates cell metabolism and growth, 
whereas mTORc2 affects cell proliferation and survival 
in a cell-type-specific manner [42]. Inhibition of mTOR 
by VD was previously described in osteoblasts [25] and 
more recently it was also demonstrated that VD adminis-
tration downregulates mTOR in  CD4+ T cells during rat 
EAE [56]. As an alternative pathway, c-Jun N-terminal 
kinases (JNK) pathway has also been implicated in the 
regulation of GR expression [51]. JNK belongs to a highly 
preserved ubiquitous signaling pathway, the mitogen-acti-
vated protein (MAP) kinases [41] and activation of JNK 
was found to be associated with a poor response to GCs 
in patients with Crohn’s disease [41]. Here, we set out 
to investigate the potential synergistic effects of VD and 
GCs in vitro, in EAE and in MS patients in the context of 
acute relapses, and to unravel the cellular and molecular 
mechanisms underlying the effects of VD on GC therapy. 
We found that VD increases the efficacy of GC treatment 
by upregulating the GR via mTORc1 in T cells but not by 
JNK signaling, which suggests that combination therapy 
with mTOR inhibiting substances bears the potential to 
overcome GC resistance in the treatment of MS relapses.
Materials and methods
The active metabolite 1,25(OH)2D3 (1,25D) was used in 
all in vitro and in vivo studies. Further, it was measured 
in murine serum samples to assess bioavailability after 
oral gavage of 1,25D. For human serum concentrations, 
25-hydroxyvitamin D (25D) was analyzed as it represents 
the body’s VD supply [18].
Studies with human samples
Human studies were approved by the cantonal ethics com-
mittee Bern and the local ethics committee of Ruhr-Uni-
versity Bochum and Goettingen (5408-15, 4801-13, 2017-
00060, 2017-01369, E08-910, 19-09-10).  CD3+ T cells 
were isolated using gradient centrifugation and negative 
magnetic cell sorting (Pan T cell isolation  kit®, Miltenyi 
Biotec, Cologne, Germany). 1 × 106/ml T cells (RPMI, Inv-
itrogen, Karlsruhe, Germany; 10% FCS, Sigma-Aldrich, St. 
Louis, USA; 1% Penicillin/Streptomycin (PenStrep), Invit-
rogen; l-Glutamine, Invitrogen, Sigma-Aldrich) were stim-
ulated with phytohemagglutinin (PHA, 0.5 µg/ml, Sigma-
Aldrich) and treated with control (solvent: 0.1% DMSO), 
10 nM 1,25D (MedChem Express, South Brunswick, New 
Jersey, USA) or 75 µM methylprednisolone (MP, MIBE 
GmbH, Brehna, Germany) or the combination of 1,25D/MP 
(37 °C, 5%  CO2). Furthermore, the mTOR inhibitors rapa-
mycin (5.5 nM, Millipore, Darmstadt, Germany), voxtalisib 
(1.57 µM, MedChemExpress), and everolimus (2 nM, Seleck 
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Chemicals, Houston, Texas USA) as well as the JNK inhibi-
tor SP600125 (10 nM, MedChem Express) were used alone 
or in combination with 75 µM MP. T cell apoptosis was ana-
lyzed by flow cytometry (FACS) after 24 or 72 h (annexin V/
propidium iodide, Becton–Dickinson Bioscience, Franklin 
Lakes, New Jersey, USA). For the analysis of GR expression, 
 CD3+ T cells (1 × 106/ml) from healthy donors (HD, n = 6) 
were seeded in a poly-l-lysine-coated 96-well plate (10 µg/
ml, Sigma-Aldrich). Cells were treated with control (solvent: 
0.1% DMSO) or 1,25D for 24 h (10 nM, 100 nM; 37 °C, 5% 
 CO2), and the GR was quantified by ELISA according to the 
manufacturer’s protocol (NR3C1 Human Cell-Based ELISA 
kit, Abnova, Taipei, Taiwan). Data are expressed as ratio of 
optic density (OD)450 GR/glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH).
To test whether the GR is differentially regulated in dif-
ferent T cell subsets, human GR was analyzed by western 
blot in  CD4+ and  CD8+ T cells. Cells were isolated from 
frozen PBMC collected after GC administration (negative 
selection;  CD4+ T Cell Isolation Kit, human;  CD8+ T Cell 
Isolation Kit, human; Miltenyi Biotec; Germany). After 
lysis (10% trichloroacetic acid buffer, Fluka, Switzerland), 
western blots were stained with following antibodies and 
analyzed with Fusion Imaging System (Vilber Lourmat, 
France): Anti-GR, 1:50,000 (abcam, United Kingdom); 
Anti-HSP90, 1:1000 (Cell Signaling, Massachusetts); Anti-
GAPDH, 1:10,000 (abcam, United Kingdom); Goat Anti-
Rabbit IgG (H + L) HRP, 1:3000 (Bio-Rad, California). In 
addition, early active demyelinating MS lesions, obtained 
via stereotactic biopsy before GC administration, were co-
stained for GR and either CD3, CD4 or CD8.  The following 
antibodies were used for staining of paraffin slices: Anti-
GR, 1:300 (Cell Signaling Technology); Anti-CD3, 1:50 
(Zytomed System, Berlin, Germany); Anti-CD4, 1:100 
(Zytomed System); Anti-CD8, 1:250 (CellMarque, Rock-
lin, USA) [30].
A retrospective chart analysis identified stable MS 
patients (initial cohort; University of Bochum, n = 56, 
McDonald criteria; relapsing phenotype, no relapse or 
intravenous GCs within the last 3 months) and MS patients 
during acute relapse (initial cohort: n = 54; < 30 days since 
symptom onset). An independent validation cohort included 
n = 85 patients (stable MS, n = 40; MS relapse, n = 45, Uni-
versity of Bern). Relapse definition followed standard crite-
ria [13]. Patients were defined as GC responsive if they no 
longer showed relapse-associated neurological symptoms 
within 2 months from relapse onset (initial cohort n = 30; 
validation cohort n = 20) [17]. In line with current guidelines 
[13], patients with insufficient clinical response as defined 
by clinical experts (e.g. visual acuity < 0.5 or EDSS pyrami-
dal functional subscore > 3) to ≥ 2 high-dose GC pulses (e.g. 
500–2000 mg MP over 3–5 days) underwent treatment inten-
sification with plasma exchange within 6 weeks after relapse 
onset. These patients were classified as GC resistant (initial 
cohort n = 24; validation cohort n = 25) [43].
Serum levels of 25D, which represent the body’s VD sup-
ply, were analyzed by electro-chemiluminescence binding 
assay (initial cohort:  Elecsys®, Roche, Basel, Switzerland). 
For analysis of 25D and 1,25D serum levels in the independ-
ent validation cohort,  Liason® 25D Total Assay and 1,25D 
Assay were used (DiaSorin Inc, Stillwater, USA).
For gene expression analyses,  CD8+ T cells (from 63 
healthy donors and 49 MS patients) were isolated using 
gradient centrifugation and magnetic cell sorting (Miltenyi 
Biotec). A WT expression kit (Life technologies, Carlsbad, 
California, USA) was used to generate and amplify sense 
strand DNA for fragmentation and labeling using a Gene 
Chip WT terminal labelling kit (Affymetrix, Santa Clara, 
California, USA). Samples were hybridized to Affymetrix 
Human gene 1.0 ST chips (Affymetrix), containing 764,885 
distinct oligonucleotide features consolidated into 33,297 
probe sets. The Bioconductor Affymetrix package was then 
used to perform robust multichip average computations. 
Unwanted variation from the expression data was removed 
using the remove unwanted variation two-step method.
Animal studies
Animal studies were approved by the local authorities 
(Office of Agriculture and Nature Bern, Switzerland; no. 
BE 101/16; Regional Office for Nature, Environment and 
Consumer Protection of North Rhine-Westphalia, Germany: 
no. 84-02.04.2015.A051). Mice were bred under conven-
tional housing conditions at the in-house animal facilities 
of the University of Bern, the Ruhr University Bochum and 
the University Medical Center Goettingen. In addition to 
C57BL/6 and BALB/c wild-type (WT) mice (Janvier Labs, 
Le Genest-Saint-Isle, France), we also used animals with 
altered GR signaling:  GRwt (Nr3c1) and  GRdim  (Nr3c1tm3GSc) 
mice on a BALB/c background;  GRflox  (Nr3c1tm2GSc) and 
 GRlck  (Nr3c1tm2GScTg(lck-cre)1Cwi) mice on a C57BL/6 back-
ground [7, 25].  GRlck mice do not express the GR specifi-
cally in T cells [7], whereas a point mutation present in 
 GRdim mice impairs GR-mediated effects due to impaired 
dimerization of the receptor in all cell types. Other GR sign-
aling pathways are preserved in  GRdim mice [37]. C57BL/6 
 Rheblck (mTORc1 KO) has a T cell-specific depletion of 
mTORc1 activity as described previously [9].
Splenic  CD3+ T cells were isolated from WT,  GRdim and 
 Rheblck mice by magnetic cell sorting (Pan T cell isolation 
 kit®, Miltenyi Biotec). 1 × 106/ml T cells [RPMI media, FCS 
10%, PenStrep 1%, l-glutamine 1% (Sigma-Aldrich)] were 
stimulated with concanavalin A (ConA, 1.5ug/ml, Sigma-
Aldrich) and treated with control (solvent: 0.1% DMSO), 
1,25D (10 nM and 100 nM) and MP (6–600 nM, 24–48 h, 
37 °C, 5%  CO2). The viability of these T cells was analyzed 
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by FACS (annexin V/propidium iodide staining). For the 
analysis of mTOR inhibition, T cells were treated with dif-
ferent concentrations of 1,25D (10 and 100 nM) or rapamy-
cin (547 pM) in vitro (24 h). After lysis (HEPES 50 mM, 
NaCl 150 mM, glycerol 10%, EDTA 1 mM, Nonidet P-40, 
1%), western blot was performed to determine mTORc1 
activity (Phospho-p70 S6 Kinase (phP70S6K), Cell Signal-
ing Technology, Danvers, USA, 1:500; beta-Actin, Sigma-
Aldrich, 1:15,000). Protein expression is presented as the 
densitometric ratio of target to housekeeping protein (Image 
Studio 4.0, LI-COR, Lincoln, USA). To test GR regulation 
by 1,25D in regard to mTORc1 signaling, T cells from WT 
and  Rheblck mice were treated in vitro for 24 h with control 
(solvent: 0.1% DMSO) or 1,25D (10 nM). GR concentration 
was measured using a commercial available ELISA (Mouse 
GR ELISA kit; MyBioSource, San Diego, USA). For EAE 
experiments WT,  GRlck as well as  Rheblck on C57Bl6 back-
ground mice were used. Induction of  MOG35–55 EAE fol-
lowed our previously described protocols [45]. Briefly, 
animals were immunized by a subcutaneous injection of 
100 µg  MOG35–55 peptide (Institute of Medical Immunol-
ogy, Charité, Berlin, Germany) in PBS (Thermofischer, 
Dreieich, Germany) emulsified in complete Freund’s adju-
vant containing 100 µg Mycobacterium tuberculosis H37RA 
(Difco, Detroit, Michigan, USA), followed by 200 ng pertus-
sis toxin (Quadratech, Epsom, United Kingdom) (i.p., days 0 
and 2). Animals were scored daily in a blinded manner using 
a 10-point EAE scale: 0, normal; 1, reduced tone of tail; 2, 
limp tail, impaired righting; 3, absent righting; 4, gait ataxia; 
5, mild paraparesis of hind limbs; 6, moderate paraparesis; 
7, severe paraparesis or paraplegia; 8, tetraparesis; 9, mori-
bund; 10, death [45]. Treatment was initiated when ≥ 50% 
of the animals had an EAE score ≥ 2.
MP (0.8 mg/kg/day or 4 mg/kg/day i.p.), 1,25D (10 ng/
day, oral gavage), everolimus (5 mg/kg/day, oral gavage), 
SP600125 (15 mg/kg/day, oral gavage) and controls (sol-
vents for MP: PBS i.p.; for 1,25D/everolimus/SP600125: 
DMSO in peanut oil p.o., Byodo, Mühldorf am Inn, Ger-
many) were given on three consecutive days. Due to dual 
drug administration in the combination therapy arm, the 
control group received two control substances (solvents PBS 
i.p. and DMSO (in peanut oil p.o.). Further, each mono-
therapy arm received the control substance of the respective 
other drug (e.g. MP monotherapy: MP in PBS and DMSO 
in peanut oil p.o. as 1,25D/everolimus control substance).
For the analysis of the bioavailability of oral 1,25D used 
during EAE experiments, we determined peak serum level 
of 1,25D. For this purpose, 1,25D (10 ng/day) or control 
(solvent: DMSO in peanut oil) was fed via oral gavage over 
three consecutive days and blood was collected on day 3, 4 h 
after last 1,25D administration. Murine 1,25D serum levels 
were determined using a chemiluminescence immunoassay 
 (LIAISON®, DiaSorin, Stillwater, MN, USA).
Statistical analysis
All statistical analyses were performed with  SPSS® 20 (IBM 
Corporation, Armonk New York, USA). Spearman’s Rho 
was used for correlation analysis. The effect of mTOR/JNK 
inhibitor or 1,25D on MP-induced T cell apoptosis (human/
murine) and GR protein expression was evaluated by a Wil-
coxon signed-rank test. Further, Mann–Whitney test was 
applied for comparison of murine 1,25D serum concentra-
tions and ex vivo apoptosis in animals fed with 1,25D or 
control. For comparison of categorical data sets, Chi-square 
test was run. Kruskal–Wallis test adjusted for multiple com-
parisons using Bonferroni correction was performed for 
analysis of EAE disease course, 25D serum concentration 
and gene expression of key regulators of mTORc1 activity. 
Further, a multivariate logistic regression analysis was used 
to calculate the risk of a GC-resistant relapse in MS patients 
with severe 25D deficiency.
Results
1,25D increases glucocorticoid‑induced apoptosis 
of human and murine T cells via upregulation 
of the glucocorticoid receptor
Given the proposed importance of the expression level of the 
GR in clinical GC resistance, we first investigated whether 
1,25D modifies GR protein levels in human T cells. As 
depicted in Fig. 1a, 1,25D (10 and 100 nM) increased GR 
expression in a dose-dependent manner in vitro. In line with 
this observation, GR gene expression in  CD8+ T cells from a 
different cohort demonstrated a moderate reduction in indi-
viduals with severe 25D deficiency (mean (SE) log2 GR gene 
expression: serum 25D level: < 25 nmol/l: 9.94 (0.14), n = 5 
(n = 2 healthy controls/n = 3 stable MS patients); ≥ 25 nmol/l: 
10.09 (0.14), n = 107 (n = 61 healthy controls/n = 46 sta-
ble MS), p < 0.05, Affymetrix human gene 1.0 ST chip). 
To address the functional relevance of 1,25D-induced GR 
upregulation, we employed the GR-dependent model of GC-
induced  CD3+ T cell apoptosis in vitro. Using a concentra-
tion of 75 µM methylprednisolone (MP), which is achieved by 
intravenous pulse therapy during treatment of MS relapses [1], 
co-incubation with 1,25D (10 nM) led to a higher apoptosis 
rate of human T cells compared to MP alone (Fig. 1b). We 
next examined whether the synergistic 1,25D/MP effects that 
we observed in vitro could also be detected in mice ex vivo. 
For this purpose, C57BL/6 WT mice were fed with 1,25D or 
control (control: DMSO in peanut oil) on three consecutive 
days before splenic T cells were isolated and incubated in vitro 
for 24 h with MP. Pre-treatment of animals with 1,25D led to 
increased GC-induced apoptosis of murine T cells over a broad 
MP dose range (1.1–1.3-fold, p < 0.01, Online Resource 1). 
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To test whether the observed synergistic effect of 1,25D on 
GC-induced T cell apoptosis was mediated via the GR, we 
utilized rodent cells with a functional impairment of the GR 
 (GRdim). These cells harbor a point mutation that compromises 
GR dimerization; however, other GR signaling pathways are 
preserved, which explains residual effects of GCs to induce 
apoptosis in  GRdim T cells [37]. A synergistic effect of 1,25D 
and MP on the induction of T cell apoptosis was observed in T 
cells with a functional GR  (GRwt, Fig. 1c), whereas this effect 
was not detectable in  GRdim T cells (Fig. 1d).
1,25D augments therapeutic efficacy 
of methylprednisolone in  MOG35–55 experimental 
autoimmune encephalomyelitis in a glucocorticoid 
receptor‑dependent manner
To determine the bioavailability of our therapeutic oral 
1,25D dose regime in mice, serum levels of 1,25D were 
tested 4 h after last 1,25D application. After oral gavage, 
serum 1,25D levels increased 6.1-fold in mice treated on 
three consecutive days with 10 ng 1,25D compared to control 
Fig. 1  a GR protein expression normalized to glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) after incubation of human  CD3+ T 
cells with 1,25D in vitro (24 h; PHA 0.5 µg/ml; n = 6 per group. Cell-
based ELISA). Data are expressed as ratio of optical density (OD) 
450 GR/GAPDH. b Apoptosis of human  CD3+ T cells of healthy 
donors. Incubation with control (solvent: 0.1% DMSO), 1,25D, 
MP or 1,25D + MP in vitro (72 h; PHA 0.5 µg/ml; n = 7 per group; 
Annexin V/PI, flow cytometry). Apoptosis of murine splenic-derived 
 CD3+ T cells from c BALB/c  GRwt (wild type) or d BALB/c  GRdim 
mice. Incubation with control (solvent: 0.1% DMSO), 1,25D, MP or 
1,25D + MP in vitro (24 h; ConA 1.5 µg/ml; n = 9–10  (GRwt); n = 5 
 (GRdim); Annexin V/PI, flow cytometry). Apoptosis is depicted as 
increase over control (–; control: solvent 0.1% DMSO). In the con-
trol groups of each genotype, mean percentage of apoptotic murine 
T cells (SE) was as follows: BALB/c  GRwt 46.1% (4.3) vs BALB/c 
 GRdim 42.3% (3.6). GR glucocorticoid receptor, OD optical density, 
1,25D 1,25(OH)2D3, MP methylprednisolone, SE standard error. Sta-
tistics: Wilcoxon signed-rank test: # < 0.05
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treatment (control: DMSO in peanut oil; Fig. 2a). For EAE 
experiments, we attempted to mimic GC pulse therapy of 
MS by treating the mice for three consecutive days starting 
at the onset of moderate signs of EAE. Mice first received 
doses of both substances (MP 0.8 mg/kg; 1,25D 10 ng) 
that had previously been demonstrated to only moderately 
improve symptoms of EAE [4, 53]. Whereas monotherapy 
with MP at this suboptimal dose did not lead to significant 
changes of clinical scores, 1,25D monotherapy resulted in 
mild clinical improvement compared to control treatment 
(control: PBS i.p. + DMSO in peanut oil p.o.; improvement 
of mean cumulative EAE score by 10.6%; p < 0.05, Fig. 2b). 
In contrast, strongest clinical effects were observed for the 
combination of 1,25D and MP (compared to control treat-
ment reduction of mean cumulative EAE score by 19.1%, 
p < 0.001, Fig. 2b). To more closely resemble the situation 
in patients during MS relapse therapy, a higher GC dose (MP 
4 mg/kg [37]) was used (Fig. 2c). Here, compared to control 
treatment (PBS i.p. + DMSO in peanut oil p.o.) respective 
monotherapies reduced the mean cumulative EAE score by 
Fig. 2  a Murine 1,25D serum concentration after 3 days of oral gav-
age with 1,25D 10 ng/day or control (solvent: DMSO in peanut oil). 
Cardiac blood was sampled 4 h after the last oral gavage (n = 5 per 
group, chemiluminescence immunoassay). Clinical disease course 
of  MOG35–55 EAE in C57BL/6 wild-type mice b, c or  GRlck mice 
devoid of the T cell GR d treated for three consecutive days with con-
trol (DMSO in peanut oil), 1,25D (10  ng/day), MP [b intermediate 
MP dosage (0.8 mg/kg/day), c, d high MP dosage (4.0 mg/kg/day)] 
or 1,25D + MP. Downwards arrow: days of treatment. EAE score: 
10-score system according to Ref. [45]. Numbers of included animals 
are given in the figure. EAE experimental autoimmune encephalo-
myelitis, GRlck mice with glucocorticoid receptor deficient T cells, 
GRwt glucocorticoid receptor wild type, MP methylprednisolone, SE 
standard error, 1,25D 1,25(OH)2D3. Statistics: a Mann–Whitney test: 
## < 0.01, b–d Kruskal–Wallis test: # < 0.05; ### ≤ 0.001
Acta Neuropathologica 
1 3
14.1% (MP 4 mg/kg) and 18.3% (1,25D 10 ng/day; each 
p < 0.001). Again, the strongest effect was observed for the 
MP/1,25D combination therapy, which ameliorated EAE 
disease score by 35.5% (p < 0.001; Fig. 2c). We next exam-
ined whether the synergistic effect of the 1,25D and MP 
combination therapy was dependent on the GR. In mice that 
are devoid of the GR in T cells  (GRlck), this therapeutic com-
bination regime did not lead to any clinical effects (Fig. 2d).
25D levels are reduced in MS patients 
with glucocorticoid‑resistant relapses 
and T cell apoptosis is exclusively 
augmented by 1,25D in MS patients 
with glucocorticoid‑resistant MS relapses
To address the potential relevance of our findings concern-
ing the 1,25D/GC synergism in patients, we investigated 
25D serum concentrations in patients with stable MS in 
comparison with patients with GC-responsive and GC-
resistant MS relapses. Patient populations did not differ in 
gender or MS disease duration (Online Resource 2, initial 
cohort). Although GC-resistant patients were younger than 
those with GC-responsive MS relapses, age was not associ-
ated with 25D serum levels (ρ − 0.076, p > 0.05, n = 110). 
Baseline disability before relapse did not differ between 
groups (Online Resource 2). During relapse and before 
steroid administration, EDSS was higher in patients with 
GC-resistant compared to GC-responsive relapse. Although 
patients with GC-responsive relapse received approximately 
3400 mg less methylprednisolone, only in these patients 
an EDSS improvement was observed. In contrast, patients 
with GC-resistant relapse even tended to further deterio-
rate despite high-dose GC treatment (Online Resource 2). 
In addition to the extent of improvement, patients with GC 
response also tended to improve more quickly after 0.5 (SD 
0.6) months, whereas EDSS analysis in GC-resistant patients 
was performed after 0.7 (0.6) months (Online Resource 2). 
In GC-resistant patients with the longest interval between 
EDSS assessments post-relapse EDSS ≥ 1.5 months after 
first EDSS; n = 3) a prominent EDSS deterioration (+ 2.7 
(2.3) was observed, arguing against delayed effects of GC.
Patients with GC-resistant relapse had polysympto-
matic relapses with on average 0.4 more clinical symptoms 
than those who responded well to GC treatment. However, 
when analyzing distribution of relapse symptoms we did 
not observe specific patterns in patients with GC-resistant 
or GC-responsive relapse (e.g. optic neuritis vs. myelitis; 
Online Resource 3). Furthermore, patients with GC-resist-
ant relapse exhibited on average 1.2 more gadolinium-
enhancing lesions compared to those with GC-responsive 
relapse (Online Resource 2). Since GC-resistant patients 
had received higher GC dosages for relapse therapy, we 
investigated whether the GC dose influences 25D serum con-
centrations before and after GC treatment in a different sub-
set of patients [median GC dosage 1665 mg (IQR 1525), min 
750, max 7000, n = 10]. Here, no differences in 25D serum 
levels were observed before and after GC administration 
[median (IQR) 25D serum levels (nmol/l) prior to GC ther-
apy: 7.2 (15.2) versus post GC pulse therapy: 10.0 (12.1), 
p > 0.05]. Overall, 25D serum levels in the initial cohort 
were almost 50% lower in MS patients with relapses than in 
stable patients [MS with relapses median (IQR): 27.6 nmol/l 
(25.7); stable MS without relapses 48.8  nmol/l (36.9); 
p < 0.01]. This difference was mainly due to the subgroup 
of patients with GC-resistant relapses. In these patients, 25D 
serum levels [21.9 (21.3) nmol/l] were 21% lower compared 
to GC-responsive MS (p < 0.05) and 55% lower compared 
to stable MS (p ≤ 0.001; Fig. 3a). A classification of 25D 
serum levels into established categories (< 25 nmol/l: severe 
deficiency; 25–49.9 nmol/l: deficiency; ≥ 50 nmol/l: suffi-
cient 25D supply [18, 21]) demonstrated that 66.7% of GC-
resistant MS patients were severely 25D deficient in contrast 
to only 26.7% of GC-responsive and 21.4% of stable MS 
patients. The influence of 25D serum concentration on GC 
efficacy was further validated using a multivariate logistic 
regression analysis adjusted for age, gender, MS disease 
duration, and presence of disease-modifying MS treatment. 
MS patients who experienced an acute relapse (n = 54) but 
did not exhibit severe 25D deficiency had a considerably 
higher likelihood of responding to GC pulse therapy than 
patients with severe 25D deficiency (odds ratio 10.6; 95% 
confidence interval 2.2–51.5, p < 0.05). Findings of reduced 
25D serum concentrations in GC-resistant patients were val-
idated using an independent cohort of RMS patients (vali-
dation cohort, n = 85, see Online Resource 4 for baseline 
characteristics). Also in this cohort, GC-resistant patients 
(n = 25) had lower 25D levels than stable (n = 40) and GC-
responsive MS patients (n = 20, Fig. 3b). 1,25D values in 
this validation cohort did not demonstrate a correlation with 
25D serum levels or a different distribution within the three 
MS patient groups (Online Resource 5). We next addressed 
whether the biologically active form of 25D, 1,25D, differen-
tially affects GC-induced T cell apoptosis in GC-responsive 
(n = 8) and GC-resistant (n = 5) MS patients during relapse. 
Patients did not differ in gender, age, disease duration or the 
presence of immunotherapy (Online Resource 6). GC-resist-
ant MS patients had received 2.7-fold higher dosage of GCs 
during GC pulse therapy (p < 0.05). Despite higher GC dos-
ages, baseline apoptosis after GC therapy tended to be lower 
in these patients compared to patients with GC-responsive 
relapse (Fig. 4, p > 0.05). In GC-responsive MS patients, 
the addition of 1,25D (10 nM) did not lead to an additional 
effect of MP-induced T cell apoptosis in vitro (Fig. 4a). In 
contrast, 1,25D led to an increase of MP-induced apoptosis 
in T cells from GC-resistant MS patients (Fig. 4b, p < 0.05). 
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To address if rather  CD4+ or  CD8+ T cells are involved, 
we investigated GR as well as HSP90-protein expression in 
blood-derived T cells from a limited group of RMS patients 
with GC-responsive and GC-resistant relapse by western 
blot. Here, a differential regulation of GR in  CD8+ T cells 
was observed. Further a trend towards a GR regulation in 
 CD4+ T cells as well as an increase in the HSP90/GR ratio 
in both T cell subsets was found (Online Resources 7, 8). 
In addition, active demyelinating MS lesions in brain biop-
sies of three patients (one with GC-resistant and two with 
GC-responsive relapse) were investigated to evaluate  GR+ T 
cells in situ. Here, a pronounced infiltration of  CD3+ as well 
as  CD4+ and  CD8+ T cells was present in the two patients 
with GC-responsive relapse compared to the single patient 
Fig. 3  25D serum concentrations in nmol/L of patients with relapsing 
multiple sclerosis (RMS) in the initial cohort (a) and the validation 
cohort (b). Blood sampling was performed during stable disease (ini-
tial cohort: n = 56, validation cohort: n = 40), glucocorticoid-respon-
sive relapse (validation cohort: n = 30, validation cohort: n = 20) or 
glucocorticoid-resistant relapse (initial cohort: n = 24, validation 
cohort: n = 25). 25D 25-hydroxyvitamin D. Statistics: Kruskal–Wallis 
test: # < 0.05, ### ≤ 0.001
Fig. 4  a Apoptosis of  CD3+ T cells of MS patients during glucocor-
ticoid-responsive relapse (n = 8) or b glucocorticoid-resistant relapse 
(n = 5). Incubation with control (solvent: 0.1% DMSO), 1,25D, MP 
or 1,25D + MP in vitro for 72 h (PHA 0.5 µg/ml; Annexin V/PI, flow 
cytometry). GR glucocorticoid receptor, MP methylprednisolone, 
RMS relapsing multiple sclerosis, 25D 25-hydroxyvitamin D, 1,25D 
1,25(OH)2D3. Statistics: Wilcoxon signed-rank test: # < 0.05
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with GC-resistant relapse (Online Resources 9, 10). How-
ever, in this limited number of samples, no differences in GR 
expression were observed between phenotypes and between 
T cell subsets.
Synergistic effects of 1,25D and glucocorticoids are 
mediated by inhibition of mTORc1 signaling
We next addressed if mTOR or JNK signaling pathways, 
both implicated in the regulation of GR expression, are also 
involved in the observed 1,25D/GC synergism. In murine 
T cells, 1,25D reduced protein expression of the mTORc1 
downstream target phP70S6 K in a dose-dependent manner, 
proving the inhibition of mTORc1 activity (Fig. 5a). Like-
wise, gene expression of a key regulator of mTORc1 activity 
in human  CD8+ T cells from a large cohort (Online Resource 
11) was associated with 25D serum levels. Thus, expression 
of tuberous sclerosis complex (TSC)-1 was reduced in indi-
viduals with severe 25D deficiency (< 25 nmol/l; n = 5 (n = 2 
healthy controls/n = 3 stable MS patients)) compared to indi-
viduals with 25D levels between 25–49.9 nmol/l (deficient; 
n = 42 (n = 24 healthy controls/n = 18 stable MS patients)) 
Fig. 5  a Protein expression of phospho-P70 S6 Kinase (phP70S6K, 
downstream target of mTORc1) normalized to β-actin expres-
sion. Murine  CD3+ T cells were incubated with control (solvent: 
0.1% DMSO), 1,25D or rapamycin in  vitro (24  h; ConA 1.5  µg/
ml; n = 2 independent experiments, densitometry of western blots). 
b Log2 expression of TSC-1 gene in human  CD8+ T cells in asso-
ciation with 25D serum concentrations (< 25  nmol/l; n = 5 (n = 2 
healthy controls/n = 3 stable MS patients); 25–49.9  nmol/l; n = 42 
(n = 24 healthy controls/n = 18 stable MS patients); ≥ 50  nmol/l; 
n = 65 (n = 37 healthy controls/n = 28 stable MS patients); see Online 
Resource 11; Affymetrix Human gene 1.0ST chip). c Apoptosis of 
human  CD3+ T cells of healthy donors. Incubation with control (sol-
vent: 0.1% DMSO), methylprednisolone and different mTOR inhibi-
tors: voxtalisib (n = 4 in duplicates;) rapamycin (n = 5) and everoli-
mus (n = 6 in duplicates) in vitro (24 h; PHA 0.5 µg/ml, Annexin V/
PI, flow cytometry). d Disease course of  MOG35–55 EAE in C57BL/6 
wild type treated with control (solvent: DMSO in peanut oil), everoli-
mus (5 mg/kg/day), MP (0.8 mg/kg/day) or everolimus + MP. Down-
wards arrow: days of treatment. EAE score: 10-score system accord-
ing to Ref. [45]. Numbers of included animals are given in the figure. 
MS multiple sclerosis, MP methylprednisolone, GR glucocorticoid 
receptor, phP70S6K phospho-p70 S6 kinase, Rapa rapamycin, SE 
standard error, TSC-1 tuberous sclerosis complex 1, 25D 25-hydrox-
yvitamin D, 1,25D 1,25(OH)2D3; Vox voxtalisib, Statistics: b, d 
Kruskal–Wallis test: # < 0.05; ## ≤ 0.01; c Wilcoxon signed-rank test: 
# < 0.05; ## ≤ 0.01
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or with sufficient levels (≥ 50 nmol/l; n = 65 (n = 37 healthy 
controls/n = 28 stable MS patients); Fig. 5b). No associa-
tions between 25D serum levels and Akt, TSC-2 or Rheb 
gene expression were observed (data not shown). We next 
demonstrated that three different types of mTOR inhibitors 
increased GC-induced apoptosis in human T cells (Fig. 5c), 
indicating a class-specific effect. In contrast, GC co-incuba-
tion with SP600125, a pharmacological JNK inhibitor [5], 
did not alter GC-induced human T cell apoptosis (Online 
Resource 12A) and had no therapeutic effect on GC treat-
ment efficacy in EAE (Online Resource 12B).
To further investigate the relevance of the mTORc1 
pathway for 1,25D/GC synergism, we used murine T cells 
deficient in mTORc1 signaling  (Rheblck). In these cells, 
1,25D failed to upregulate GR and to increase GC-induced 
apoptosis (Fig. 6a, b). Further, in EAE, combined 1,25D/
GC treatment in  Rheblck mice worsened clinical disease 
course in comparison with control treatment (control: PBS 
i.p. + DMSO in peanut oil p.o.; Fig. 6c). We next assessed 
the impact of pharmacological mTORc1 inhibition on 
EAE using everolimus, a rapalog, which allosterically and 
specifically blocks mTORc1 activity [10]. Everolimus 
was administered in a dose (5 mg/kg, p.o.) that was dem-
onstrated to result in a strong mTORc1 inhibition in vivo 
[11]. Whereas respective monotherapies did not have any 
relevant effect on clinical EAE disease course compared to 
control treatment (control: PBS i.p. + DMSO in peanut oil 
p.o.), the combination therapy with everolimus and MP led 
to a decrease of EAE disease severity by 23.5% compared 
to control (Fig. 5d, p < 0.01).
Discussion
Given the central role of the GR in mediating clinical GC 
resistance [38], we investigated if VD augments GC efficacy 
via modulation of GR expression [39].
We found that 1,25D increased GR protein levels and 
enhanced GC responsiveness in vitro and in vivo. Syner-
gistic efficacy of the 1,25D/GC combination therapy was 
dependent on the GR in T cells as demonstrated using two 
different mouse models with reduced or absent GR signaling. 
Fig. 6  a GR protein concentration in ng/ml after incubation of murine 
 CD3+ T cells  (Rheblck vs.  Rhebwt) with 1,25D in vitro (24 h; ConA 
1.5  µg/ml, n = 5; ELISA). b Apoptosis of murine splenic-derived 
 CD3+ T cells from C57BL/6  Rhebwt or  Rheblck mice. Incuba-
tion with control (solvent: 0.1% DMSO), 1,25D 100 nM, MP 6 nM 
or 1,25D + MP in  vitro (24  h; ConA 1.5  µg/ml; n = 3 in duplicates; 
Annexin V/PI, flow cytometry). c Disease course of  MOG35–55 EAE 
in  Rheblck treated for three consecutive days with control (solvent: 
DMSO in peanut oil) or 1,25D (10  ng/day) + MP (0.8  mg/kg/day). 
Downwards arrow: days of treatment. EAE score: 10-score system 
according to Ref. [45]. Numbers of included animals are given in 
the figure. GR glucocorticosteroid receptor, MP methylpredniso-
lone, Rheb ras homolog enriched in brain, SE standard error, 1,25D 
1,25(OH)2D3, 95% CI 95% confidence interval. Statistics: a, b Wil-
coxon signed-rank test: # < 0.05; c, d Kruskal–Wallis test: ## ≤ 0.01, 
### ≤ 0.001
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Low 25D serum levels were associated with decreased GR 
mRNA expression in human T cells and MS patients with 
profound 25D deficiency were more likely to exhibit clinical 
resistance to GCs during relapse. Likewise, 1,25D increased 
GC effects in vitro only in T cells from GC-resistant MS 
patients. Several findings point to a crucial role of mTORc1 
signaling in mediating 1,25D/GC functional synergism. 
Severe 25D deficiency was associated with a downregula-
tion of an archetype mTORc1 inhibitor in human T cells. 
In animals with T cell-specific depletion of mTORc1, the 
synergistic 1,25D/GC effects on GR upregulation, T cell 
apoptosis and therapeutic efficacy in EAE were abolished. 
Finally, treatment with a specific mTORc1 inhibitor also 
augmented therapeutic GC efficacy in EAE.
An association of hypovitaminosis D (25D-deficiency) 
and increased use of steroids was described for other inflam-
matory diseases such as asthma and inflammatory bowel 
disease [20, 47], and different effector cells and mecha-
nisms have been implied in mediating this effect. In EAE, 
T cells appear to be pivotal in mediating synergistic effects 
of 1,25D and GC, since T cell-specific deletion of either 
GR or mTORc1 abrogated these effects. This fits well with 
previous data demonstrating lack of efficacy of GC mono-
therapy in EAE only when the GR is deleted in T cells, 
but not in monocytes, macrophages and microglia [54]. 
Upregulation of the GR has been associated with a better 
prognosis and increased clinical efficacy of GC treatment in 
several immune-mediated and malignant diseases [28, 50]. 
It is noteworthy that the GR can either regulate gene tran-
scription through binding to GC-responsive elements (GRE) 
presented in regulatory DNA regions, or by interacting with 
transcription factors such as nuclear factor kappa B or acti-
vator protein-1 [16]. In  GRdim mice, dimerization of the GR 
and thus its ability to bind to GREs are strongly impaired. 
As a consequence, regulation of at least a subset of genes 
by the GR is abolished [37]. The lack of any 1,25D/GC syn-
ergism in  GRdim cells, therefore, argues that altered gene 
expression is relevant for the observed effects being in line 
with the finding of increased GR binding to a GRE after pre-
incubation with VD [57]. We demonstrated clear synergism 
of 1,25D with MP as the evidence-based GC for the treat-
ment of acute MS relapse. As the synergism is mediated via 
an upregulation of the GR, it appears likely that this effect is 
not specific for MP and might be used to increase efficacy of 
other GCs, e.g. dexamethasone. In vitro, VD/dexamethasone 
combination suppresses the activation of synovial fibroblasts 
via modulation of  CCR6+ T-helper memory cells [8]. We 
did not observe any clinical effect of 1,25D monotherapy 
in mice with a T cell-specific GR-deficiency, in contrast to 
robust efficacy in WT mice, in line with the well-known VD 
effects on  MOG35–55 EAE [7, 56]. Since the VD receptor and 
GR are located on different chromosomes (VDR: 12q13.11; 
GR: 5q31.3 [32]), a coincidental knock-out of both receptors 
by the Cre recombinase expressed in  GRlck T cells appears 
unlikely. Therefore, we speculate that the GR might also be 
relevant for specific immunological effects of VD, a hypoth-
esis that warrants further investigation.
For the analysis of systemic VD supply in our MS patient 
cohorts, the major circulating metabolite (25D) was used 
because it has a longer half-life than bioactive 1,25D and is 
less influenced by hormones or medications [24]. Reduced 
25D serum levels in patients with GC-resistant relapse com-
pared to stable patients and patients with GC-responsive 
relapse were observed in two independent cohorts of RMS 
patients. Lack of correlation of 1,25D with 25D serum lev-
els points to higher sensitivity of 25D serum levels, since 
1,25D serum concentration is kept in the normal range even 
if 25D concentration is reduced [24]. In addition, systemic 
1,25D serum levels will not properly reflect local bioactive 
1,25D, since T cells and macrophages also have the abil-
ity to directly convert 25D into 1,25D at the site of action, 
which cannot be detected by analyzing serum samples [36]. 
Together, these factors argue for the use of 25D serum con-
centration as a global measure of the body’s VD supply as 
is performed in most epidemiological and interventional 
studies [3, 35].
In our multivariate analysis, corrected for various poten-
tial confounders (age, gender, MS disease duration, presence 
of disease-modifying MS treatment), severe 25D deficiency 
was associated with clinical GC resistance even after GC 
dose escalation. The clinical definition of GC resistance 
followed current national guidelines on the use of plasma 
exchange as evidence-based treatment intensification for MS 
relapses [13]. The retrospective data analysis in our patient 
cohorts is a clear limitation. Although we did not observe 
major clinical or epidemiological characteristics between 
the GC-responsive and -resistant patients that confounded 
our findings to a large extent, these cannot completely be 
excluded. Especially, masking of delayed GC effects due 
to early initiation of plasma exchange as intensified relapse 
treatment according to national guidelines cannot completely 
be ruled out [13]. However, in a more recent prospective 
double-blinded study, an EDSS improvement already after 
28 days was demonstrated which did not further change after 
180 days [22]. In addition, severely reduced 25D levels in 
GC-resistant patients in two independent cohorts also argue 
for robustness of our findings.
Also, our experimental data on the synergistic effect of 
1,25D on GC-induced apoptosis exclusively in T cells from 
GC-resistant patients argue for a true biological difference 
between the cohorts.
In patients with GC-resistant relapse, basal T cell apop-
tosis ex vivo was lower compared to steroid-responsive MS 
patients despite application of twofold higher GC dosages 
in steroid-resistant patients. This observation is in line with 
previous data demonstrating lower suppressive capacity of 
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dexamethasone on T cell proliferation in GC-resistant than 
in GC-responsive patients [29]. Peripheral  CD8+ T cells 
from a limited number of patients with GC-resistant relapse 
had a higher GR protein expression in comparison with cells 
from patients with GC-responsive relapse, similar to previ-
ous findings in peripheral mononuclear cells [29]. In early 
active demyelinating CNS lesions, in one investigated GC-
resistant patient there were less T cells, albeit the expression 
of the GR did not appear to differ between patients with and 
without GC response. These preliminary findings will have 
to be followed up also with respect to the presumed site of 
action of GC.
Concerning the signaling mechanism for 1,25D/GC 
synergism, we identified a role of the mTORc1 but not the 
JNK pathway downstream of VD. Both genetic deletion and 
pharmacological inhibition point to mTORc1 inhibition as 
major mechanism mediating 1,25D/GC synergism. In indi-
viduals with severe 25D-deficiency TSC-1 gene expression 
was reduced. Since TSC-1 is an archetype mTORc1 inhibitor 
[19], downregulation of TSC-1 would result in a disinhibi-
tion of the mTORc1 pathway. Furthermore, our in vitro data 
indicated a functional inhibition of mTORc1 enzyme activ-
ity by 1,25D in T cells, with inhibition of phosphorylation 
of a downstream target of mTORc1.
In vitro, T cells from  Rheblck mice have a T cell-specific 
depletion of mTORc1 activity [9]. In Rheb-deficient T cells, 
1,25D did not lead to GR upregulation and these mice did 
not exhibit synergistic 1,25D/GC effects in apoptosis induc-
tion. Moreover, EAE data in  Rheblck animals also supported 
our conclusion, as we did not find any inhibitory effect on 
the disease by the 1,25D/GC combination. Similar to find-
ings reported before also in our hands active  MOG35–55 EAE 
resulted in a more cerebellar phenotype, which is presum-
ably associated with a more pronounced Th2 rather than 
Th1/Th17 CNS autoimmunity [9]. VD and GCs drive Th2 
polarization [12, 48], which could hypothetically explain 
the exacerbated disease course of  MOG35–55 EAE in  Rheblck 
mice treated with the combination of 1,25D/GC. Finally, 
synergistic effects of everolimus and GC in WT EAE mice 
point to mTORc1-inhibition as major mechanism responsi-
ble for the increased GC efficacy. Everolimus, a derivative 
of rapamycin, is a potent mTORc1 inhibitor and approved 
for the treatment of tuberous sclerosis [49]. Thus, rapid 
translation into the clinical setting of MS relapse treatment 
appears feasible, especially since its usage would be tempo-
rally restricted, potentially reducing possible adverse drug 
reactions (e.g. infections and ulcera).
Despite highly efficacious disease-modifying therapies, 
GCs remain the most commonly used substances in MS 
treatment [17, 40]. Nevertheless, approximately 30% of MS 
patients report insufficient remission and 50% suffer from 
steroid-related side effects [33]. The use of plasma exchange/
immune adsorption as treatment intensification during acute 
relapse constitutes an invasive procedure. Thus, further 
translation of alternative approaches to improve treatment 
of acute neuroinflammation would meet a high clinical need. 
However, given the high heterogeneity of relapse pheno-
types and dynamics, clinical studies face several hurdles, e.g. 
sample size and sensitive, objective readouts. Acute optic 
neuritis may represent an interesting paradigm where bio-
logically meaningful outcome parameters can be objectively 
and sensitively quantified [34]. Finally, our results may also 
harbor implications for other clinical situations, since GCs 
are widely used in the treatment of autoimmune disease and 
malignancies.
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